Question-and-Answer Session
Thank you, Mr. Squicciarino. [Operator Instructions]. And our first question comes from Donald Ellis from Thomas Weisel Partners. Please go ahead.
Donald Ellis - Thomas Weisel Partners
Thank you, and good morning. First question is regarding SKELAXIN. Year-over-year prescriptions were down about 8.5%, but the revenue reported was up about 3.5%. How much of that was stocking versus price increase?
Brian A. Markison - Chairman, President and Chief Executive Officer
Hi, this is Brian. We are getting that exact information to you right now.
Donald Ellis - Thomas Weisel Partners
Okay. I’ve got some follow-up questions. Regarding Amrex [ph] what you're seeing out there in the marketplace regarding that competitive threat from Amrex?
Brian A. Markison - Chairman, President and Chief Executive Officer
Well, what we were seeing is a much more competitive market in terms of share of voice than we had been seeing over previous years. Not too long ago, SKELAXIN was the only branded muscle relaxant in the marketplace and now we've got a couple of more entrants and we're seeing this share of voice. So it's got a meaningful impact in terms of our ability to out-shout the competition. And we have earlier answer to your question. Joe?
Joseph Squicciarino - Chief Financial Officer
Good morning, Donald. As far as stocking goes, we had a slight uptick, it was about a little more than half a week in inventory out in the trade, but it's still right at about half a month. So that was not a significant factor, and we did get a better system price versus last year.
Donald Ellis - Thomas Weisel Partners
Okay. The next question regarding the FDA advisory panel on Monday with Purdue, one of the consultants made a comment that 90%... 97% of the overdoses were due to taking the Oral [ph] as suppose to crushing the Oral and then using injectable. Doesn’t that make you guys a lot more bullish on your ACUROX product versus the REMOXY product?
Brian A. Markison - Chairman, President and Chief Executive Officer
I think there was a lot going on at that advisory panel, and I think we all learned a lot about what the FDA and what the advisers are hoping to see from industry. We're very equally bullish on both. We think we are on the right track and we remain on track as we've said earlier to file the NDA for REMOXY before the end of the second half and ACUROX by the end of the year. So we're bullish about both.
- To read the full transcript on Seeking Alpha, click here »
